St. Jude Clinical Trials
3CAR: B7-H3-specific CAR T-cell Therapy for Children and Young Adults with Solid Tumors
B7-H3-specific Chimeric Antigen Receptor Autologous T-cell Therapy for Pediatric Patients with Solid Tumors (3CAR)
Diseases Treated:
Solid Tumors
Eligibility:
Inclusion criteria include:
- 21 years old or younger
- Relapsed or refractory B7-H3-positive solid tumor
*First 3 patients must be at least 12 years old.
FLOPET: PET Scan Studies to Analyze Neuroblastoma and Pheochromocytoma Tumors
18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma
Diseases Treated:
Neuroblastoma, pheochromocytoma
Eligibility:
This study is open to St. Jude patients only.
- Known or suspected neuroblastoma or pheochromocytoma
- At least 1 year old
RBAPP: Smartphone App for Retinoblastoma
Determination of the Sensitivity and Specificity of a Smartphone Application to Detect Retinoblastoma
Diseases Treated:
Eligibility:
This study is currently open only to patients at St. Jude Children's Research Hospital.
- 7 years old or younger
- Part I
- Diagnosed with retinoblastoma and has not received any treatment OR
- Diagnosed with cataracts and has not received any treatment OR
- Diagnosed with glaucoma and has not received any treatment
- Part II
- Referred to an eye doctor to check for leukocoria or other eye conditions
- Part III
- Diagnosed with retinoblastoma and is receiving treatment
SJATRT: Phase II Study of Alisertib Therapy for Rhabdoid Tumors
Phase II Study of Alisertib as a Single Agent in Recurrent or Progressive Central Nervous System (CNS) Atypical Teratoid Rhabdoid Tumors (ATRT) and Extra-CNS Malignant Rhabdoid Tumors (MRT) and in Combination Therapy in Newly Diagnosed ATRT
Diseases Treated:
Brain Tumor : Recurrent, progressive, or newly diagnosed atypical teratoid rhabdoid brain tumors (ATRT)
Solid Tumor : Progressive extra-CNS malignant rhabdoid solid tumors (MRT)
Eligibility:
- Has one of these types of tumors:
- Newly diagnosed atypical teratoid rhabdoid tumors (ATRTs) or synchronous extraneural ATRTs
- ATRTs or malignant rhabdoid tumors (MRTs) that have come back after previous treatment (recurrent disease)
- ATRTs or MRTs that are growing after previous treatment (progressive disease)
- 21 years of age or younger
SJRET6: Combination Chemotherapy in Treating Patients with Newly Diagnosed, Previously Untreated Intraocular Retinoblastoma
Protocol for the Study and Treatment of Participants with Intraocular Retinoblastoma
Diseases Treated:
Eligibility:
- Newly diagnosed retinoblastoma that has not spread beyond the eye
- Has not received previous treatment with chemotherapy or radiation therapy
- Patients who have been diagnosed with retinoblastoma in one eye who did not receive chemotherapy, but then developed retinoblastoma in the opposite eye
Collaborative Clinical Trials
ADV1414: Phase I Study of Selinexor to Treat Patients with Recurrent and Refractory Pediatric Solid Tumors
Diseases Treated:
Eligibility:
- Diagnosis of solid tumor that is resistant to other anticancer therapy or has come back after therapy. Includes lymphoma and central nervous system (CNS) tumors that may or may not require surgery.
- Fully recovered from the acute toxic effects of all prior anticancer therapy
- At least 1 but not more than 21 years of age
- Able to swallow tablets whole
ADVL1823: Larotrectinib (LOXO-101) in Children with TRK Fusion Solid Tumors and Relapsed Leukemia
Diseases Treated:
Eligibility:
- 21 years old or younger (at St. Jude)
- Newly diagnosed infantile fibrosarcoma or solid tumor with NTRK1, NTRK2 or NTRK3 fusion OR
- Relapsed/refractory acute leukemia with NTRK1, NTRK2 or NTRK3 fusion
LOXORET: Phase I/II Study of LOXO-292 (Selpercatinib) in Patients with Advanced RET-Altered Solid Tumors or Brain Tumors
Diseases Treated:
Solid tumors, Brain tumors
Eligibility:
- 6 months to 21 years old
- Solid tumor or brain tumor that has progressed or spread
- Failed standard treatment
- RET gene alteration
MEKPEM: A Phase I/II trial of MK-3475 (pembrolizumab) in children’s solid tumors and lymphomas
Diseases Treated:
Advanced melanoma or PD-L1 positive advanced relapsed or refractory solid tumor or lymphoma or high-grade glioma
Eligibility:
- Between 6 months and 18 years old with diagnosis of MSI-H solid tumor OR
- Between 12 years and 18 years old with diagnosis of melanoma OR
- Between 3 and 18 years old with relapsed or refractory classical Hodgkin lymphoma
- Negative pregnancy test 72 hours prior to medication administration in participants of child-bearing potential
- Appropriate liver and kidney functions
NBL1232: Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-High Risk Neuroblastoma
Diseases Treated:
Neuroblastoma, ganglioneuroblastoma
Eligibility:
- Participant has been enrolled on ANBLB1 (ANBL00B1).
- Participant has newly diagnosed MYCN non-amplified neuroblastoma or MYCN non-amplified ganglioneuroblastoma.
- Participant is less than 12 months (Group A) and less than 18 months (Group B and Group C) of age at diagnosis.
PBTC45: MK-3475 in Treating Children with Recurrent, Progressive or Refractory HGGs, DIPGs and Hypermutated Brain Tumors
Diseases Treated:
Recurrent, progressive, or refractory high-grade gliomas
Eligibility:
- Participant has recurrent, progressive or refractory non-brainstem high-grade glioma or diffuse intrinsic pontine glioma (DIPG)
- Participant is 1 to 18 years of age
- Participant has bi-measurable disease on MRI
- Participant has received prior radiation therapy and/or chemotherapy and has not received myelosuppressive anticancer chemotherapy for at least three (3) weeks
PNOC013: Study of REGN2810 Immunotherapy in Children with Relapsed or Refractory Solid or CNS Tumors and Study of REGN2810 combined with radiation in Children with Newly Diagnosed or Recurrent Glioma
Diseases Treated:
Diffuse Intrinsic Pontine Glioma, Glioma, CNS Tumor, Solid Tumor
Eligibility:
- Diagnosed with one of the following:
- Recurrent or refractory solid tumor or central nervous system (CNS) tumor
- Diffuse Intrinsic Pontine Glioma (DIPG)
- Newly diagnosed or recurrent high-grade glioma
- Younger than 18 years old (Phase I) or between 3 and 25 years old (Efficacy Phase)